Arsenite-induced aryl hydrocarbon receptor nuclear translocation results in additive induction of phase I and synergistic induction of phase II genes*

Simone Kann¹, Ming-ya Huang, Cameron Estes, John F. Reichard, Maureen A. Sartor, Ying Xia and Alvaro Puga

Center for Environmental Genetics and Department of Environmental Health,

University of Cincinnati Medical Center, P.O. Box 670056

Cincinnati, Ohio 45267-0056
Running Title: Arsenite induces AHR translocation

Corresponding author:

Alvaro Puga

Department of Environmental Health, University of Cincinnati Medical Center

P.O. Box 670056. Cincinnati, OH 45367-00567

(Messenger Mail, use: 123 E. Shields St. Cincinnati, OH 45220)

Phone: (513) 558-0916; FAX: (513) 558-0925

E-mail: Alvaro.Puga@UC.EDU

This manuscript contains 35 text pages

8 figures

1 Table

50 references

Abstract: 249 words

Introduction: 792 words

Discussion: 1,152 words

Abbreviations:

3M4NF: 3'-methoxy-4'-nitroflavone; AHR: Aryl hydrocarbon (Ah) receptor; AHRE: AHR response element; ARNT: Ah receptor nuclear translocator; B[a]P: Benzo[a]pyrene; bHLH: Basic region-helix-loop-helix; HLH: Halogenated aromatic hydrocarbons; MEF: Mouse embryonic fibroblasts; PAH: Polycyclic aromatic hydrocarbons; PAS: Per-AHR-ARNT-Sim; PBS: Phosphate-buffered saline; TBHQ: Tert-butylhydroquinone; TCDD: Tetrachlorodibenzo-p-dioxin.
ABSTRACT

Complex mixtures of carcinogenic metalloids, such as arsenic, and PAHs or HAHs are common environmental contaminants. The biological consequences of exposure to these mixtures are unpredictable and, although the health effects of individual chemicals may be known, the toxicity of environmental mixtures is largely unexplored. Arsenic, not a potent mutagen by itself, is comutagenic with many DNA-damaging agents. Mixtures of arsenite plus B[a]P augment B[a]P mutagenicity, suggesting that arsenite might uncouple expression of phase I and phase II genes responsible for detoxification. We have studied the effects of arsenite exposure on the activation of the AHR and its subsequent role in gene transactivation. Treatment of mouse Hepa-1 cells with arsenite induces AHR nuclear translocation and binding to the Cyp1a1 gene promoter with the same efficiency as TCDD, the AHR most potent ligand; however, TCDD and B[a]P are one order of magnitude more potent than arsenite in up-regulating Cyp1a1 transcription. Global profiling analyses of cells treated with arsenite plus B[a]P indicate that several phase I and phase II detoxification genes are in some cases additively and in others synergistically deregulated by the mixtures. Real-time RT-PCR analyses of MEFs showed that the mixtures had an additive effect on the mRNA levels of Cyp1b1, a prototypical phase I detoxification gene, and an AHR-dependent synergistic effect on the corresponding levels of Nqo1, a prototypical phase II gene. We conclude that exposure to arsenite/B[a]P mixtures causes regulatory changes in the expression of detoxification genes that ultimately affect the metabolic activation and disposition of toxicants.
INTRODUCTION

One of the current problems in toxicology is the lack of information on the health effects of complex chemical mixtures. Data are scarce, and the task of reproducing every possible complex mixture of toxicants to analyze its effects would be herculean. Yet rarely environmental exposures to toxic or carcinogenic compounds result from the presence of a single, isolated toxic agent. Complex mixtures often include a combination of metals and PAHs. Of these, arsenic and B[\(\alpha\)]P, respectively, remain among the most frequent mixtures in the environment and are found among the top 20 hazardous substances in the ATSDR/EPA priority list. Of more than 9,000 superfund sites where PAHs are major contaminants, a full 50% have also arsenic as a co-contaminant.

Arsenic, a known carcinogen, is most commonly found in the environment as arsenate (As\(^{5+}\)), although arsenite (As\(^{3+}\)) is the most toxic and the most likely carcinogenic species in humans (Tinwell et al., 1991). Arsenic consistently fails to show carcinogenic effects in rodent models unless it is used at very high doses (Wang and Rossman, 1996). The initial observation that arsenic was comutagenic with ultraviolet light led to the concept that arsenic carcinogenicity resulted from the activation of genes that enhanced the effect of the primary carcinogen (Wang and Rossman, 1996). Using gene arrays, arsenite has been shown to be a potent deregulator of gene expression, particularly of genes involved in oxidative stress responses (Rea et al., 2003; Andrew et al., 2003). The ability of arsenite to bind to and oxidize vicinal dithiols within a protein or to bridge two thiols between two proteins has suggested the possibility that one of the mechanisms of gene inactivation by arsenic may involve the oxidation of transcription factors and protein kinases with vicinal thiols, such as are found in zinc-finger transactivators, and the ensuing changes in the ability of the oxidized factors to function (Wang and Rossman, 1996). This concept was
proven correct at least for the inactivation of NFkB activity by the reaction of arsenite with critical cysteines in the Ikβ−kinases (Kapahi et al., 2000; Roussel and Barchowsky, 2000).

The Ah receptor (AHR) is a ligand-activated bHLH/PAS transcription factor that forms heterodimers with the Ah receptor nuclear translocator ARNT and binds to cis-acting AHRE enhancer elements in the regulatory domains of target genes, such as the cytochrome P450 Cyp1a1 and the NAD(P)H-dependent quinone oxidoreductase Nqo1, leading to changes in chromatin structure and activation of gene transcription. The role of non-AHR ligands as modifiers of Ah receptor-dependent responses has been much less well studied than the role of ligands, such as B[a]P or TCDD in the toxic responses that they induce. Recent reports have demonstrated that modification of Ah receptor-dependent gene expression can result from oxidative stress, suggesting that co-exposure to receptor ligands and pro-oxidant environmental pollutants could disrupt the coordinate regulation of detoxification genes. The precise step in the AHR signaling pathway that is acted upon by oxidative stress is not clear. Sulfhydryl modifying agents have been shown to block binding of TCDD to the AHR (Denison et al., 1987; Kester and Gasiewicz, 1987) and binding of AHR to DNA (Ireland et al., 1995), suggesting that AHR activation may be directly regulated by redox changes. In addition, H2O2 has been shown to inhibit Cyp1a1 inducibility, although this effect may be mediated through transcription factors other than the AHR (Barker et al., 1994; Morel and Barouki, 1998; Xu and Pasco, 1998).

The ability of arsenic and other metals and metalloids to generate oxidative stress has been extensively investigated (Nieboer and Fletcher, 1996; Stohs and Bagchi, 1995) but their potential to modify AHR-dependent gene expression and to modulate the toxicity of AHR ligands such as B[a]P is almost unknown. Our previous results have shown that low concentrations of sodium arsenite had a strong synergistic effect in the genotoxicity of
B[a]P, an effect that required CYP1A1-dependent metabolism (Maier et al., 2002). These results suggested the possibility that the combined exposure to arsenite and B[a]P might disrupt the regulatory mechanisms that control transcription from B[a]P-inducible gene promoters and cause an uncoupling of phase I and phase II gene expression with a concomitant imbalance in B[a]P metabolism. We have tested this hypothesis by studying the effects of arsenite exposure on the activation of the AHR and its subsequent role in the transactivation of phase I and phase II genes. We find that treatment of mouse hepatoma Hepa-1 cells with arsenite induces AHR nuclear translocation and binding to the Cyp1a1 gene promoter with the same efficiency as TCDD, its most potent ligand; however, TCDD and B[a]P up-regulate Cyp1a1 transcription to a much greater extent than arsenite. In contrast, global profiling and real-time RT-PCR analyses of gene expression indicate that several phase II detoxification genes are in some cases additively and in others synergistically deregulated by arsenite plus B[a]P treatment.
MATERIALS AND METHODS

Cell culture and chemical treatments. Cells known to respond to a B[a]P or TCDD challenge by activation the AHR included the mouse hepatoma Hepa-1c1c7 cell line (Bernhard et al., 1973) and MEFs from Ahr+/+ C57BL/6J mice (Tan et al., 2002). MEFs from Ahr−/− mice (Fernandez-Salguero et al., 1995) do not transactivate detoxification genes after a TCDD or a B[a]P challenge (Tan et al., 2002). MEFs were prepared by standard techniques from 14.5-day old embryos and were grown in α-minimal essential medium (Invitrogen) supplemented with 5% FBS, 100 µg/ml penicillin and 100 µg/ml streptomycin. Treatments were applied when the cells were at 80-90% confluence. Sodium arsenite was freshly dissolved at 1,000X strength in sterile deionized water prior to use. TCDD and B[a]P were added to the cells dissolved in DMSO at concentrations of 5 nM and 5 µM, respectively. DHT was dissolved in ethanol and used at 1 nM. Control cells received an equal volume of DMSO or ethanol, never to exceed a final concentration of 0.1% in the cell cultures. Tert-butylhydroquinone was dissolved in sterile deionized water and used at 25 µM. The AHR antagonist 3M4NF (Nazarenko et al., 2001), a gift from Dr. Thomas Gasiewicz, was dissolved in DMSO and used at 1 µM.

Immunofluorescence staining. Cells grown on cover glasses were fixed for 15 min with 3.7% paraformaldehyde in PBS, washed with PBS three times, permeabilized and reacted at 30° C for 1 h with an affinity-purified rabbit anti-AHR raised in our laboratory against a N-terminal peptide of the mouse AHR. These antibodies were affinity purified with the peptide immunogen and showed similar specificities against AHR proteins as those commercially available from BioMol and those that were a generous gift from Dr. Richard Pollenz. This was followed by staining with a rhodamine-labeled goat anti-rabbit IgG in
the presence of 1 mg/ml of the DNA dye bis benzimide Hoescht 33258 for 30 min. Fluorescence was visualized using a Zeiss fluorescence microscope. A total of 5 - 10 fields were evaluated for each treatment group.

**Electrophoretic mobility shift assays.** Nuclear extracts were prepared by procedures described previously (Puga et al., 2000) with minor modifications. Cells were washed twice with ice cold PBS, harvested by scraping and collected by centrifugation. Pelleted cells were resuspended in 100 mM NaCl, 20 mM Tris-HCl pH8.0, 1mM EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF, 0.1 mM NaVO₄, 10 mM NaF, 10 mM NaP₂O₇, 0.5% NP-40 and lysed for five minutes on ice and dounced with 20 strokes of a loose-fitting homogenizer. Nuclei were pelleted at low speed and nuclear extracts were obtained in a final volume of 100 µl of a buffer containing 2mM EDTA, 2 mM dithiothreitol, 0.4 M KCl, 10% glycerol and 25 mM HEPES, pH 7.9, at a protein concentration of 10-20 µg /µl.

DNA-binding reactions were performed in a 20-µl reaction volume with 10,000 dpm (approximately 0.1 ng) of double-stranded AHRE probe (Puga et al., 2000) and 5 - 15 µg nuclear protein, in a buffer containing 1mM EDTA, 1 mM dithiothreitol, 80 mM KCl, 10% glycerol, 1 µg poly(dI-dC)-poly(dI-dC) carrier and 20 mM HEPES, pH 7.8. One strand of each complementary pair of oligonucleotides was end-labeled with T4 polynucleotide kinase and [γ-³²P]-ATP, and annealed to an excess of the unlabeled complementary oligonucleotide. Binding reactions were allowed to proceed for 20 min at room temperature and samples were loaded onto non-denaturing 4% polyacrylamide gels. Following electrophoresis at 200 V for 2 - 3 h in 0.5X Tris-borate buffer, the gels were dehydrated and exposed to X-ray film.
Western blot analysis. To prepare nuclear extracts for immunoblotting the above protocol was modified such that the final nuclei pellets were resuspended in lysis buffer and briefly sonicated to disrupt the nuclei. Debris was removed by centrifugation at 12,000 rpm for 15 min. Protein concentration of the supernatants was determined and the supernatants were stored at -80°C until ready to use. Ten micrograms of protein were resolved by electrophoresis in 7% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were blocked with 5% low-fat milk in PBST (0.1 M PBS with 0.1% Tween 20) and incubated for 1 h at room temperature with the appropriate primary antibody at 1:1000 to 1:5000 dilution in PBST containing 3% BSA. In addition to the anti-AHR, anti-HSP90 (Santa Cruz Biotechnology) was also used. After washing the blots with PBST, the membrane was incubated for 1 h in 1:10,000 goat anti-rabbit HRP-conjugated antibody (Santa Cruz) in PBST containing 5% milk. After washing, bands were visualized using PicoWest Chemiluminescent Super Signal (Pierce Rickford, IL). The same procedure was used for detection of β-actin using and anti-β-actin antibody generously provided by Dr. James L. Lessard (Cincinnati Children’s Hospital Medical Center).

RNA isolation and real-time RT-PCR. Total RNA was isolated using Tri Reagent (Invitrogen) according to the manufacturer’s instructions with additional purification steps applied to RNA samples used for microarray analysis. To verify RNA quality prior to labeling for microarray analyses, samples were analyzed using an Agilent 2100 Bioanalyzer. cDNA was synthesized by reverse transcription of 20 µg total RNA in a total volume of 30 µl containing 1X reverse transcriptase buffer, 2.5 µM random hexamers, 0.25 mM dNTP, 0.01 M dithiothreitol, 20 U of Rnasin and 200 U of SuperScript™ II RNase H− reverse transcriptase (Invitrogen). Samples were incubated at 42°C for 1 h and the reverse transcriptase was inactivated by heating to 99°C for 5 min. For real-time PCR
amplification, 3 µl of cDNA were amplified with mouse Cyp1a1 primers 5’-GCCTTCATTCTGGAGACCTTCC-3’ and 5’-CAATGGTCTCTCCGATGC-3’, giving a product of 280 bp. Amplification of Cyp1b1 was with primers 5’-AAGGAAGGGAGTGCGATAG-3’ and 5’-ATGGGGGAGATAGGAGGAAAGG-3’, giving a product of 227 bp. Amplification of Nqo1 cDNA was with primers 5’-ACCCCACTCTATTTTGTCC-3’ and 5’-ACTTACTCCTTTTCCCATCCTC-3’, giving a product size of 279 bp. B-actin amplification of the same cDNA samples was used as an internal standard. Amplification was conducted in the Smart Cycler (Cepheid, Sunnyvale, CA) in a total volume of 25 µl consisting of 1 X Brilliant™ SYBR® Green QPCR Master Mix (Stratagene) and 0.4 µM primers. The reaction mixtures were heated to 95°C for 10 min and immediately cycled 40 times through a 24 sec denaturing step at 95°C, a 60 sec annealing step at 55°C and a 46 sec elongation step at 72°C. Cycle threshold (C_T) of each sample was automatically determined to be the first cycle at which a significant increase in optical signal above an arbitrary baseline set at 30 fluorescence units was detected. All determinations were done in triplicate. The values shown represent the C_T ratios of experimental to control cells treated with DMSO, normalized to the β-actin mRNA level in the same sample.

**Fluorescent labeling of target cDNAs and high-density microarray hybridization.** Total RNA was isolated using Tri Reagent (Invitrogen) according to the manufacturer’s instructions with additional purification steps applied to RNA samples used for microarray analysis. To verify RNA quality prior to labeling for microarray analyses, samples were analyzed using an Agilent 2100 Bioanalyzer. Labeling of cDNAs, preparation of microarrays, and hybridization reactions were performed by the University of Cincinnati.
Functional Genomics Core and are briefly described here. Fluorescence labeled cDNAs were synthesized from 20 µg of total RNA using an indirect amino allyl labeling method (DeRisi et al., 1996). The cDNA was synthesized by an oligo(dT)-primed, reverse transcriptase reaction, and the cDNA was labeled with monofunctional reactive Cytidine-3 and Cytidine-5 dyes (Cy3 and Cy5; Amersham; Piscataway, NJ). Specific details of the labeling protocols may be found at http://microarray.uc.edu.

The hybridization probes were from arrayed mouse oligonucleotide microarrays derived from the Operon/Qiagen Verified Libraries containing 13,332 sequences from annotated mouse genes, affixed each in a 100 µm diameter spot to polylysine-treated microscope slides. The hybridization targets were the paired Cy-3 and Cy-5-labeled control and test cDNAs, which were mixed in approximately equal proportions and applied to the microarray for hybridization under high stringency conditions. After hybridization and washing unhybridized targets, Cy3 (green) and Cy5 (red) fluorescent channels were simultaneously scanned with independent lasers at 10 µm resolution. Each comparison was done in duplicate with flipped dye arrays to allow for the removal of gene specific dye effects.

**Data analysis and normalization.** Microarray hybridization data representing raw spot intensities generated by the GenePix software were analyzed to identify differentially expressed genes under different experimental conditions. Data normalization was performed in three steps for each microarray separately. First, channel specific local background intensities were subtracted from the median intensity of each channel (Cy3 and Cy5). Second, background adjusted intensities were log-transformed and the differences (R) and averages (A) of log-transformed values were calculated as $R = \log_2(X1) - \log_2(X2)$ and $A = [\log_2(X1) + \log_2(X2)]/2$, where $X1$ and $X2$ denote the Cy5 and Cy3 intensities.
after subtracting local backgrounds, respectively. Third, data centering was performed by fitting the array-specific local regression model of R as a function of A (Dudoit et al., 2002). The difference between the observed log-ratio and the corresponding fitted value represented the normalized log-transformed gene expression ratio. Normalized log-intensities for the two channels were then calculated by adding a half of the normalized ratio to A for the Cy5 channel and subtracting half of the normalized ratio from A for the Cy3 channel.

**Identification of differentially expressed genes.** The statistical analysis was performed for each gene separately by fitting the following mixed effects linear model (Wolfinger et al., 2001): \( Y_{ijk} = \mu + A_i + S_j + C_k + \epsilon_{ijk} \), where \( Y_{ijk} \) corresponds to the normalized log-intensity on the \( i^{th} \) array (\( i = 1, \ldots, 15 \)), with the \( j^{th} \) treatment combination (\( j = 1, \ldots, 5 \)), and labeled with the \( k^{th} \) dye (\( k = 1 \) for Cy5, and \( 2 \) for Cy3). \( \mu \) is the overall mean log-intensity, \( A_i \) is the effect of the \( i^{th} \) array, \( S_j \) is the effect of the \( j^{th} \) treatment combination and \( C_k \) is the effect of the \( k^{th} \) dye. Assumptions about model parameters were the same as described elsewhere (Wolfinger et al., 2001), with array effects assumed to be random, and treatment and dye effects assumed to be fixed. Statistical significance of the differential expression between different treatment combinations, after adjusting for the array and dye effects, was assessed by calculating \( p \)-values for corresponding linear contrasts. Multiple hypothesis testing adjustment was performed by calculating false discovery rate values (Benjamini and Hochberg, 1995; Reiner et al., 2003). Cut-off for significantly deregulated genes was set at a ratio of 2 above or below control values and, for all the genes presented in Table 1 the false discovery rate was <0.1. Data normalization and statistical analyses were performed using SAS statistical software package (SAS Institute Inc., Cary, North Carolina). Gene
ontology annotations were extracted from the National Center for Bioinformatics web site http://www.ncbi.nlm.nih.gov/RefSeq/.

**Cytotoxicity determinations.** Cytotoxicity of arsenic was determined by measuring lactic dehydrogenase release from treated cells, as previously described (Maier et al., 2000). No significant cytotoxicity was observed by concentrations of arsenite of 25 µM and below for up to 24 hrs post-treatment. This is also clearly evident in the fluorescent micrographs in the figures.
RESULTS

Arsenite induces AHR nuclear translocation. To test the hypothesis that combined exposures to arsenic and B[a]P could disrupt expression of phase I and phase II detoxification genes, we studied potential effects of arsenite exposure on AHR activation. To this effect, we measured changes in cellular compartmentalization of the AHR in mouse hepatoma Hepa-1 cells following exposure to increasing doses of sodium arsenite using immunocytochemical, Western immunoblotting and electrophoretic mobility shift assays. Immunocytochemistry with specific anti-AHR antibodies 90 minutes post-treatment showed dose response effects on nuclear translocation. At low micromolar arsenite concentrations, between 3 µM and 6 µM, there was no difference between control and arsenite-treated cells, with the AHR showing cytoplasmic localization. At concentrations of 12 µM and higher, AHR localization became patently nuclear, an effect indistinguishable from that observed in the positive control cells treated with 5 nM TCDD (Fig. 1).

We chose the 12 µM arsenite concentration to do a time response analysis. Nuclear translocation was evident by 2 hours and continued until 8 hours, the last experimental determination, closely paralleling the time response of control cells treated with 5 nM TCDD (Fig. 2). By 8 hours, however, both arsenite- and TCDD-treated cells showed a diffuse staining pattern, consistent with loss of AHR from the nucleus, as described by others (Pollenz, 2002).

To confirm the above results at the biochemical level, we prepared nuclear extracts from arsenite-treated and control Hepa-1 cells and examined them for the presence of the AHR by immunoblotting and electrophoretic mobility shift assays. Western blots were more sensitive than immunocytochemistry and dose-dependent AHR nuclear translocation...
was already detectable at the 6 µM dose and increased with dose (Fig. 3A). In time response experiments, nuclear translocation appeared to proceed at a slower rate in arsenite-treated cells than in their TCDD-treated counterparts. Maximum accumulation took place at 2 – 4 hours after arsenite treatment, whereas by 1 hour, TCDD-treated cells shown maximum nuclear AHR levels (Fig. 3B). Down-regulation of nuclear AHR also appear to be faster after TCDD treatment, with significant decreases by 4 hours after treatment, while loses of nuclear AHR were not evident until 8 hours after arsenite treatment (Fig. 3B).

Current evidence indicates that the totality of the cytosolic AHR complex translocates to the nucleus upon TCDD activation of the receptor, including the Hsp90 chaperone molecules (Pollenz, 2002). To determine whether arsenite-induced AHR nuclear translocation also extended to Hsp90, we used anti-Hsp90 antibodies in Western blots of the same nuclear extracts. Increases in the level of nuclear sp90 were found at 2, 4 and 8 hours after TCDD but not after arsenite treatment (Fig. 3B), suggesting that arsenite-dependent translocation followed a molecular pathway different from the classical ligand-dependent pathway. Immunoblotting for β-actin confirmed that these results were not an artifact of gel loading differences.

As further confirmation of the results described above, electrophoretic mobility shift assays showed dose-dependent increases in the DNA-binding activity of nuclear AHR complexes (Fig. 3C).

3M4NF is a flavonoid compound and AHR antagonist that blocks AHR nuclear translocation (Nazarenko et al., 2001). Immunocytochemistry and Western blot analysis of Hepa-1 cells showed inhibition of AHR nuclear translocation in controls simultaneously
treated with TCDD and 3M4NF, but not in cells treated with 3M4NF and arsenite (Fig. 4A and B).

The results described above strongly indicate that arsenite exposure causes the nuclear translocation of the AHR by mechanisms unlike those followed by ligands. At least the Hsp90 component of the chaperone complex does not appear to translocate with the AHR and translocation is not inhibited by 3M4NF.

**AHR-dependent gene expression is only weakly up-regulated by arsenite.** To determine whether arsenite-mediated AHR nuclear translocation and DNA-binding activation resulted in gene transactivation, we measured the induction of the cytochrome P450 Cyp1a1 gene in Hepa-1 hepatoma cells after treatment with various concentrations of sodium arsenite and compared it to the effect of induction by 5nM TCDD alone or in combination with the same concentrations of sodium arsenite. Total RNA was extracted from these cells and Cyp1a1 mRNA levels were determined by real-time RT-PCR. Treatment with arsenite alone led to a weak induction of Cyp1a1, with low levels, in the range of 2- to 5-fold over control, but significantly different from vehicle-treated control cells (Fig. 5A). Treatment with TCDD induced Cyp1a1 by 35- to 40-fold, and combined treatment with TCDD and arsenite superinduced Cyp1a1 expression to levels significantly higher than those observed in cells treated with TCDD alone (Fig. 5A). These results confirm our previous conclusions that activation of the AHR by arsenite follows different molecular pathways than activation by TCDD, leading also to different outcomes in gene transactivation.

**Low-dose gene expression effects of arsenite.** In an effort to identify low-concentration effects of arsenic, we examined the consequences of co-exposures to arsenite plus B[a]P, which we have previously shown to be synergistically comutagenic (Maier et al., 2002). As measured by real-time RT-PCR, co-treatment of Hepa-1 cells with 2 μM sodium
arsenite and 5 μM B[a]P did not cause a significant increase in Cyp1a1 induction relative to the effect of B[a]P alone. Arsenite by itself was responsible for not more than a doubling in Cyp1a1 mRNA levels, which was statistically significant in comparison to vehicle-treated controls (Fig. 5B).

We also determined the effect of arsenic exposure on the induction of *Nqo1*, a prototypical phase II gene, by B[a]P. To insure that only primary effects of treatment were observed, cells we exposed only for 4 hours to 2 μM sodium arsenite, 5 μM B[a]P, or to a combined mixtures of arsenite plus B[a]P. As control for the effect on *Nqo1*, we also treated cells with 25 μM tBHQ, a classical monofunctional phase II gene inducer, and with arsenite plus tBHQ. Treatment with B[a]P plus arsenite increased slightly Cyp1a1 induction above the level found in cells treated with B[a]P alone, although the difference was not statistically significant (Fig. 6). Arsenite alone, tBHQ and the combination of tBHQ plus arsenite did not change Cyp1a1 mRNA levels (Fig. 6). The response of the *Nqo1* genes was very different. Arsenite increased by 2-fold *Nqo1* mRNA over vehicle control, a change that was statistically significant, and, when used in combination, more than doubled the effect of B[a]P, an effect that was also statistically significant (Fig. 6). In contrast, *Nqo1* induction by tBHQ was not affected by arsenite (Fig. 6). These results suggested that the combination of arsenite and B[a]P had different regulatory consequences depending on the gene being measured and prompted us to use global gene expression profiling to investigate the extent of the response to combined treatments with these two agents.

*Global gene expression responses to low concentration mixtures of arsenite and B[a]P.*

To insure that the responses that we would observe in these experiments would not be due to genetic abnormalities resulting from long-term maintenance of cells in culture, we used
MEFs from C57BL/6J mice within 5 – 6 passages from establishment from day 14.5-old fetuses. MEFs show Ah receptor-dependent responses similar to those of hepatocytes, although they tend to express CYP1B1 instead of CYP1A1 as the predominant cytochrome P450 (Alexander et al., 1997). Genes deregulated by either 2 µM arsenite, 5 µM B[a]P or by a mixture of the two, are shown in Table 1. Several genes involved in oxidative stress responses and glutathione metabolism were upregulated by arsenic, whereas Hmox1 and two phase II detoxification genes, Aldh3a1 and Nqo1, were highly upregulated by B[a]P and by the mixture, whereas a third phase II gene, Gstp, was upregulated only by the arsenite+B[a]P mixture. Genes involved in glutathione biosynthesis, like Gclm and Gclc, and several genes coding for oxidoreductases were induced by arsenite or by arsenite+B[a]P mixtures, as were many heat shock proteins, involved in anti-apoptotic responses during oxidative stress. Among the genes deregulated by either arsenite or a mixture of B[a]P and arsenite there is a large number of genes involved in TGF-β, integrin, cell adhesion and extracellular matrix signaling processes, including TGF-β2 itself, plasminogen activator inhibitor-1, inhibin-ßA and inhibin-ßB, thrombospondin-1, at least two Adamt genes, coding for disintegrin-like metalloproteinases and other genes involved in protein glycosylation. It appears that one of the major consequences of exposure to these mixtures is the up-regulation of oxidative stress and protein chaperone responses and the down-regulation of the TGF-β pathway.

**Synergistic and additive interactions of arsenite and B[a]P in gene regulation.** For some genes in Table 1, the mRNA levels of the co-treatments appear to show additive effects in some case, synergistic in others and no effect in yet others. For example, synergy is apparent for the phase II genes Nqo1 and Aldh3a1, as well as for the oxidative stress...
sentinel---but not a phase II gene---*Hmxox1*. In contrast, *Cyp1b1*, a prototypical phase I detoxification genes, shows no cooperative effects (Table 1). To verify the gene profiling data and characterize in more detail the apparent differences between phase I and phase II genes, we measured Nqo1 and Cyp1b1 mRNA levels by real-time RT-PCR after treatment of MEFs with various concentrations of sodium arsenite, B[a]P or combinations of the two. Messenger RNA levels of Nqo1 increased with increasing concentrations of arsenite or B[a]P and showed a synergistic effect when the lower arsenite concentrations of 1 µM and 2 µM were combined with 5 µM B[a]P; however, at 5 µM arsenite, the effect was no longer synergistic, and became simply additive (Fig. 7A). There was also an observable effect of the mixture on Cyp1b1 mRNA levels, but the effect on this gene was additive, not synergistic, and was statistically significant only for the mixture of 2 µM arsenite plus 5 µM B[a]P. Surprisingly, mixtures of 1 or 5 µM arsenite plus 5 µM B[a]P gave rise to lower Cyp1b1 mRNA levels than 5 µM B[a]P alone (Fig. 7B). These effects seemed to be specific for the mixtures of arsenite and B[a]P, because mixtures of arsenite and the phase II inducer rBHQ did not show interactive effects in either *Nqo1* or *Cyp1b1* expression (Fig. 7A, B). Synergy between arsenite and B[a]P in the induction of Nqo1 expression depended on the presence of a functional AHR, as demonstrated by the finding that it took place only in *Ahr*+/+ but not in *Ahr*−/− MEFs (Fig. 8).
DISCUSSION

The results presented in this article indicate that treatment of cultured mouse hepatoma cells with sodium arsenite induces the nuclear translocation of the Ah receptor in a dose-dependent manner. By 6 – 12 µM, translocation was clearly evident by immunofluorescence, Western immunodetection and EMSA. AHR translocation was not competed by 3M4NF, an AHR antagonist, suggesting that arsenite-mediated translocation was not a ligand-dependent effect. Unlike ligand-dependent translocation, arsenite-dependent translocation led to a limited induction of Cyp1a1 to levels 10-fold lower than those induced by TCDD, but significantly different from controls. Arsenite plus TCDD and arsenite plus B[a]P had additive effects on the induction of Cyp1a1 in Hepa-1 cells and of Cyp1b1 in mouse MEFs, but the effect was synergistic and AHR-dependent for the induction of Nqo1, a phase II detoxification gene. Global gene profiling experiments with arsenite plus B[a]P mixtures showed the synergistic induction of several other phase II genes and of genes coding for oxidoreductases and the down-regulation of genes involved in TGF-β-signaling pathways.

Arsenic has been reported to modify Ah receptor-dependent induction of gene expression and B[a]P toxicity, although its specific effects are still controversial. Arsenic appears to have a positive interaction with B[a]P on lung tumorigenesis and to function as a cocarcinogen (Ishinishi et al., 1977; Pershagen et al., 1984). In vitro, it partially inhibits ligand-inducible CYP1A1 and CYP1A2 activities, although not the protein levels themselves (Jacobs et al., 1998), but in rats in vivo it increases inducible CYP1A1 in lung, but not in liver or kidney (Albores et al., 1995; Falkner et al., 1993). Previous work from our laboratory found that treatment with sodium arsenite had no effect on the induction of Cyp1a1 mRNA by TCDD, although it increased Nqo1 mRNA levels (Maier et al., 2000).
Minor, albeit statistically significant, increases of TCDD-dependent Cyp1a1 mRNA induction were observed by others in Hepa1c1c7 cells pretreated with arsenite (Elbekai and El-Kadi, 2004), who also reported the apparent decrease in the activities of the CYP1A enzymes. On the other hand, work from other authors has shown no change (Vakharia et al., 2001a), a small, not statistically significant decrease (Vakharia et al., 2001b) or a statistically significant reduction of 45% (Bessette et al., 2005) in Cyp1a1 mRNA levels in cells co-exposed to AHR-ligands and arsenic. At present, we have no explanation for the diversity of results that have been reported in the literature, including those shown here. Technical differences between less accurate Northern blot determinations compared with the more accurate real-time RT-PCR, or the choice of reference gene in the later, may explain the discrepancies. Resolution of the question would require the concerted effort of all the laboratories affected by these results.

The mechanisms responsible for ligand-independent activation of the Ah receptor are poorly understood. Earlier work with MG-132, an inhibitor of the 26S proteasome, showed that proteasome inhibition led to AHR nuclear translocation with (Santiago-Josefat et al., 2001) or without (Davarinos and Pollenz, 1999) a significant effect on gene induction. Similar experiments using a constitutively nuclear AHR found that treatment with the HSP90 ligand geldanamycin resulted in rapid degradation of the receptor but that inhibition of degradation by the proteasome inhibitor allowed geldanamycin to transform the nuclear AHR to form a heterodimer with ARNT that was incapable of stimulating transcription (Lees and Whitelaw, 1999). More recently, ligand-independent AHR activation by MG-132 was found to depend on increases in protein kinase C activity (Santiago-Josefat and Fernandez-Salguero, 2003), a finding consistent with the observation that AHR nuclear translocation is a function of cell density and is regulated by
phosphorylation and dephosphorylation events in the AHR nuclear export signal (Ikuta et al., 2004a;Ikuta et al., 2004b) and possibly in other domains (Minsavage et al., 2004). Arsenite has been shown to inhibit ubiquitin-dependent protein degradation and turnover of ubiquitin-substrate conjugation by inhibiting arginylation of substrate and conjugation of ubiquitin (Klemperer and Pickart, 1989;Kirkpatrick et al., 2003). It is likely that inhibition of ubiquitin-dependent degradation mimics the same effects caused by MG-132 and ultimately leads to AHR nuclear translocation. In this context, it is worth noting that degradation of the nuclear AHR appears to take place initially at a slower rate in arsenite-compared to TCDD-treated cells (Fig. 3B). Alternatively, arsenite binding to vicinal dithiols in HSP90 has been shown to block its ability to reduce cytochrome c (Nardai et al., 2000), suggesting the possibility that AHR translocation might result from disruption of the molecular interaction between receptor and chaperone. In this context it is worth noting that our results suggest that HSP90 does not translocate with AHR in arsenite-treated cells, although it does in TCDD-treated cells. These two alternatives are not mutually exclusive and might cooperate to cause the ultimate effect.

Arsenite-induced AHR nuclear translocation was considerably less efficient in transactivation than ligand-induced translocation, even though both induced DNA binding. This difference might be explained by differences in the amount of AHR complex bound in either case (compare the intensity of the lanes in the EMSA data shown in Fig. 3), or by other possible consequences of interactions between arsenite and AHR, ARNT, and any of a number of co-regulators and chromatin remodeling factors involved in AHR-dependent transactivation. Nonetheless, co-treatment with arsenite and TCDD in Hepa-1 cells caused a significant additive effect in Cyp1a1 expression. An additive effect was also evident in MEFs co-treated with low-concentration arsenite and B[a]P, but the effect was lost by 5
μM sodium arsenite, the higher arsenite concentration tested in these cells. In contrast, induction of \textit{Nqo1} by arsenite and B[a]P in both Hepa-1 and MEF cells was synergistic at the two lower concentrations, 1 and 2 μM, tested, and additive at the higher concentration of 5 μM. Neither additive nor synergistic \textit{Nqo1} induction effects were observed when arsenite was given in combination with \textit{tBHQ}, the prototypical inducer of Nrf2-dependent gene expression. \textit{Nqo1} is regulated by both antioxidants like \textit{tBHQ} and planar polycyclic aromatic hydrocarbons, like B[a]P (Nioi and Hayes, 2004). The failure of \textit{tBHQ} and arsenite to synergize suggests that synergy was not mediated by Nrf2 and the generation of oxidative stress by arsenite, but more likely, by the arsenite effects on the AHR.

Results from global gene expression analyses of co-treatment with arsenite and B[a]P point at an effect of either compound and more so of the mixture on the expression of genes in the TGF-β regulatory pathway. TCDD and B[a]P have been shown previously to repress TGF-β-regulated genes in an AHR-dependent manner (Gaido et al., 1992; Guo et al., 2004). Down-regulation of TGF-β pathways may have important consequences on the fate of cells or tissues exposed to combined mixtures of B[a]P and arsenite. Loss of differentiation or apoptotic directions may force exposed cells in a proliferative direction, which, combined with the pro-mutagenic environment provided by B[a]P, may provide initiating as well as a promoting events. We believe that this is a testable hypothesis to explain the co-mutagenic effect of arsenite and B[a]P that we have observed in previous experiments (Maier et al., 2002).
ACKNOWLEDGMENTS

We thank Dr. Thomas Gasiewicz for a gift of 3M4NF and Dr. Richard Pollenz for a gift of anti-AHR antibodies.
REFERENCES


FOOTNOTES:

This research was supported by NIEHS grants R01 ES10807, The NIEHS Center for Environmental Genetics grant P30 ES06096, the NIEHS Superfund Basic Research Program grant P42 ES04908 and by a grant from Phillip Morris USA. J.F.R. is a Postdoctoral Trainee partly supported by NIEHS T32 ES07250, Environmental Carcinogenesis and Mutagenesis Training Grant.

Address reprint requests to: Alvaro Puga, Department of Environmental Health. University of Cincinnati Medical Center. P.O. Box 670056. Cincinnati, OH 45367-00567. Phone: (513) 558-0916; FAX: (513) 558-0925.

E-mail: Alvaro.Puga@UC.EDU

1Present Address: Grünenthal GmbH. 52099 Aachen. Germany
FIGURE LEGENDS

Figure 1. Immunofluorescence microscopy of Hepa-1 cells treated with various concentrations of sodium arsenite. Cells were grown on cover glasses, treated for 90 minutes with the indicated concentrations of arsenite, fixed with 2% and reacted with an affinity-purified rabbit anti-AHR raised in our laboratory against a N-terminal peptide of the mouse AHR, followed by staining with a rhodamine-labeled goat anti-rabbit IgG in the presence of 1 mg/ml of the DNA dye bis benzimide Hoescht 33258 for 30 min. Fluorescence was visualized using a Zeiss fluorescence microscope. Panels labeled Control and 5 nM TCDD are the negative and positive controls, respectively. The panels on the left show the Hoescht staining; those on the right, the anti-AHR immunofluorescence; the identical fields are shown for both.

Figure 2. Immunofluorescence microscopy of Hepa-1 cells treated with 12 µM arsenite or 5 nM TCDD for various lengths of time. Conditions and treatments were as described in Figure 1, except that the cells were exposed to a single arsenite concentration for various lengths of time.

Figure 3. Western blot and EMSA analyses of arsenite-induced AHR nuclear translocation. (A) Nuclear extracts from Hepa-1 cells treated for 1 hour with the indicated µM concentrations of arsenite or with DMSO vehicle (C) or 5 nM TCDD were separated in polyacrylamide gels and the AHR detected with specific anti-AHR antibodies. (B) Nuclear extracts were prepared after time intervals of 1, 2, 4, and 8 hours post-treatment with 12 µM arsenite (lanes labeled A) or with 5 nM TCDD (lanes labeled T). Lane C is a nuclear extract from control DMSO-treated cells. The Western blot was probed with anti-AHR, anti-HSP90 and anti-actin antibodies, as indicated. (C) AHR EMSA of nuclear extracts from Hepa-1 cells treated for 1 hour with increasing concentrations of arsenite. AHRC
denotes the position of the AHR/ARNT DNA binding complex. Only the part of the gel relevant to AHR detection is shown.

**Figure 4. 3M4NF does not inhibit arsenite-mediate AHR nuclear translocation.** (A) Hepa-1 cells were treated with 1 µM 3M4NF or DMSO control and either left untreated or treated with 12 µM sodium arsenite or 5 nM TCDD for 90 min. Thereafter, they were process for AHR immunofluorescence as described in Figure 1. (B) Nuclear protein extracts were prepared from DMSO- or 3M4NF-treated Hepa-1 cells co-treated with TCDD (T), arsenite at various µM concentrations (A) or nothing (C). The Western blot was probed with an anti-AHR antibody.

**Figure 5. Real-time RT-PCR detection of Cyp1a1 mRNA in Hepa-1 cells treated with arsenite or with arsenite and TCDD or arsenite with B[a]P.** (A) Total RNA was extracted from cells treated with the concentrations of arsenite indicated in the abscissa in combination with DMSO vehicle or 5 nM TCDD. (B) Time course of Cyp1a1 induction following treatment with arsenite, B[a]P or a combination of the two.

**Figure 6. Comparison of regulatory changes induced by a mixture of arsenite and B[a]P in the mRNA levels of Cyp1a1 and Nqo1.** RNA from Hepa-1 cells treated for 6 hours with the indicated concentrations of arsenite, B[a]P and tBHQ, alone or in combination, was analyzed for the levels of Cyp1a1 and Nqo1.

**Figure 7. Effect of combined mixtures of arsenite, B[a]P and tBHQ on the mRNA levels of Nqo1 and Cyp1b1 in mouse embryo fibroblasts.** MEFs from C57BL/6J mice were treated for 6 hours with the concentrations of arsenite, B[a]P or tBHQ indicated in the abscissa. To minimize the complexity of the figure, the qualifiers Syn for synergy and Add for additive, are the only ones shown over specific bars of the bar graph. ANOVA comparison of induced values to controls are statistically significant (p>0.01).
Figure 8. Arsenite and B[a]P synergy in Nqo1 induction depends on the AHR. MEFs from Ahr\(^{+/+}\) and Ahr\(^{-/-}\) mice in a C57BL/6J genetic background were treated for 6 hours with the concentrations of sodium arsenite, B[a]P or both indicated in the abscissa. RNA from these cells was used for real-time RT-PCR quantitation of Nqo1 mRNA.
<table>
<thead>
<tr>
<th>Accession</th>
<th>Symbol</th>
<th>Gene name</th>
<th>BaP</th>
<th>As</th>
<th>BaP+</th>
<th>GO Process</th>
<th>GO Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>U12785</td>
<td>Aldh3a1</td>
<td>Aldehyde dehydrogenase-3A1</td>
<td>6.7</td>
<td>2.0</td>
<td>14.7</td>
<td>Oxidative metabolism</td>
<td>Aldehyde dehydrogenase activity</td>
</tr>
<tr>
<td>U12961</td>
<td>Nqo1</td>
<td>NAD(P)H quinone oxidoreductase-1</td>
<td>4.6</td>
<td>2.0</td>
<td>9.2</td>
<td>Electron transport</td>
<td>Oxidoreductase</td>
</tr>
<tr>
<td>X56824</td>
<td>Hmox1</td>
<td>Heme oxygenase-1</td>
<td>1.7</td>
<td>11.4</td>
<td>20.5</td>
<td>Heme oxidation</td>
<td>Oxidoreductase</td>
</tr>
<tr>
<td>M35021</td>
<td>Hspa1b</td>
<td>Heat shock protein, 70 kDa 1</td>
<td>1.2</td>
<td>2.6</td>
<td>5.1</td>
<td>Heat shock response. Anti-apoptosis</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>M12571</td>
<td>Hspa1a</td>
<td>Heat shock protein, 70 kDa 3</td>
<td>1.2</td>
<td>2.6</td>
<td>5.1</td>
<td>Protein folding</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>AJ404467</td>
<td>Dnmt3l</td>
<td>DNA (cytosine-5)-methyltransferase 3-like</td>
<td>-1.4</td>
<td>4.8</td>
<td>5.1</td>
<td>DNA methylation</td>
<td>Protein binding</td>
</tr>
<tr>
<td>U95053</td>
<td>Gclm</td>
<td>Glutamate-cysteine ligase modulatory subunit</td>
<td>1.7</td>
<td>2.1</td>
<td>4.5</td>
<td>Glutathione biosynthesis</td>
<td>Glutamate-cysteine ligase</td>
</tr>
<tr>
<td>U85496</td>
<td>Gclc</td>
<td>Glutamate-cysteine ligase catalytic subunit</td>
<td>1.7</td>
<td>2.2</td>
<td>4.4</td>
<td>Glutathione biosynthesis</td>
<td>Glutamate-cysteine ligase</td>
</tr>
<tr>
<td>U95607</td>
<td>Dnajb3</td>
<td>Heat shock protein 40, DNAJ-homolog</td>
<td>1.5</td>
<td>2.0</td>
<td>2.7</td>
<td>Heat shock response</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>L07577</td>
<td>Hsb1</td>
<td>Heat shock protein, 25 kDa</td>
<td>1.5</td>
<td>1.5</td>
<td>2.7</td>
<td>Heat shock response. Anti-apoptosis</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>L26163</td>
<td>Hist1h1e</td>
<td>Histone H1e</td>
<td>1.4</td>
<td>2.3</td>
<td>2.5</td>
<td>Nucleosome spacing</td>
<td>DNA binding</td>
</tr>
<tr>
<td>J05149</td>
<td>Insr</td>
<td>Insulin receptor</td>
<td>-1.1</td>
<td>2.1</td>
<td>2.1</td>
<td>Unknown</td>
<td>Protein kinase activity</td>
</tr>
<tr>
<td>ABO25408</td>
<td>Osp94</td>
<td>Osmotic stress protein</td>
<td>1.5</td>
<td>1.4</td>
<td>2.5</td>
<td>Unknown</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>U40930</td>
<td>Sqt9m1</td>
<td>Sequosome-1</td>
<td>1.3</td>
<td>1.7</td>
<td>2.5</td>
<td>Transcription cofactor</td>
<td>Binds to ubiquitin. Oxidative stress</td>
</tr>
<tr>
<td>K02236</td>
<td>Mt2</td>
<td>Metallothionein 2</td>
<td>1.4</td>
<td>1.6</td>
<td>2.1</td>
<td>Metal homeostasis</td>
<td>Metal ion binding</td>
</tr>
<tr>
<td>NM_013541</td>
<td>Gst1</td>
<td>Glutathione S-transferase, pi 2</td>
<td>1.4</td>
<td>1.9</td>
<td>2.0</td>
<td>Detoxification</td>
<td>Glutathione transferase</td>
</tr>
<tr>
<td>X15376</td>
<td>Mpo</td>
<td>Myeloperoxidase</td>
<td>-1.3</td>
<td>1.7</td>
<td>2.0</td>
<td>Oxidative stress response</td>
<td>Oxidoreductase</td>
</tr>
<tr>
<td>M39360</td>
<td>Pat1</td>
<td>Plasminogen activator inhibitor 1. Serpine 1</td>
<td>-2.3</td>
<td>2.0</td>
<td>2.0</td>
<td>Regulation of angiogenesis</td>
<td>Endopeptidase inhibitor</td>
</tr>
<tr>
<td>NM_010444</td>
<td>Nra4a</td>
<td>Nuclear receptor subfamily 4, group A, member 1</td>
<td>-2.3</td>
<td>2.6</td>
<td>3.5</td>
<td>Terminal differentiation</td>
<td>Nuclear receptor activation</td>
</tr>
<tr>
<td>X66820</td>
<td>Inhib</td>
<td>Inhibin beta-B</td>
<td>1.2</td>
<td>2.4</td>
<td>2.0</td>
<td>Cell growth and differentiation</td>
<td>Growth factor activity</td>
</tr>
<tr>
<td>M87276</td>
<td>Thbs1</td>
<td>Thrombospondin 1</td>
<td>-1.3</td>
<td>2.3</td>
<td>2.1</td>
<td>Cell adhesion</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td>AF118855</td>
<td>Tpt</td>
<td>Trans-prenyltransferase</td>
<td>-1.6</td>
<td>2.3</td>
<td>2.2</td>
<td>Unknown</td>
<td>Transferrase</td>
</tr>
<tr>
<td>NM_025711</td>
<td>Asp1</td>
<td>Asporin</td>
<td>1.2</td>
<td>2.3</td>
<td>2.1</td>
<td>Extracellular matrix</td>
<td>Small molecule transport</td>
</tr>
<tr>
<td>NM_010512</td>
<td>Igf1</td>
<td>Insulin-like growth factor 1</td>
<td>1.6</td>
<td>2.8</td>
<td>2.5</td>
<td>Protein folding</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>U25096</td>
<td>Klf2</td>
<td>Kruppel-like factor 2 (lung)</td>
<td>-1.2</td>
<td>2.0</td>
<td>2.5</td>
<td>Transcription regulation</td>
<td>DNA binding</td>
</tr>
<tr>
<td>D50411</td>
<td>Adami12</td>
<td>A disintegrin and metalloproteinase domain 12 (meltrin alpha)</td>
<td>-1.3</td>
<td>2.1</td>
<td>2.6</td>
<td>Cell adhesion, extracellular matrix</td>
<td>Metalloproteinase</td>
</tr>
<tr>
<td>NM_172053</td>
<td>Adami16</td>
<td>A disintegrin-like and metalloproteinase (reploysen)</td>
<td>-1.3</td>
<td>2.1</td>
<td>2.6</td>
<td>Integrin-mediated signaling</td>
<td>Metalloproteinase</td>
</tr>
<tr>
<td>X96814</td>
<td>Slat8e5</td>
<td>Slat8e5 transferase 8E</td>
<td>-1.8</td>
<td>2.3</td>
<td>2.4</td>
<td>Protein glycosylation</td>
<td>ATP binding during oxidative stress</td>
</tr>
<tr>
<td>U25254</td>
<td>Has2</td>
<td>Hyaluronan synthase 2</td>
<td>-1.5</td>
<td>2.4</td>
<td>2.4</td>
<td>Protein glycosylation</td>
<td>Transferrase</td>
</tr>
<tr>
<td>ABO24923</td>
<td>Sgcd</td>
<td>Sarcoglycan, delta (dystrophin-associated glycoprotein)</td>
<td>-2.0</td>
<td>1.0</td>
<td>2.0</td>
<td>Cytoskeleton organization</td>
<td>Protein binding</td>
</tr>
<tr>
<td>X85999</td>
<td>Itrap</td>
<td>Interleukin receptor 1 accessory protein</td>
<td>-2.1</td>
<td>1.2</td>
<td>2.6</td>
<td>Cytokine-mediated signaling</td>
<td>Protein binding</td>
</tr>
<tr>
<td>L85713</td>
<td>Phoslphopase Ob</td>
<td>-3.3</td>
<td>1.9</td>
<td>2.1</td>
<td>Intracellular signaling</td>
<td>PI phospholipase</td>
<td></td>
</tr>
<tr>
<td>X95281</td>
<td>Dhrs</td>
<td>Retinal short-chain dehydrogenase/reductase 1</td>
<td>-2.4</td>
<td>1.3</td>
<td>2.4</td>
<td>Metabolism</td>
<td>Oxidoreductase</td>
</tr>
<tr>
<td>L09562</td>
<td>Pipg</td>
<td>Protein tyrosine phosphatase, receptor type, G</td>
<td>-2.7</td>
<td>1.3</td>
<td>2.5</td>
<td>Transmembrane signaling</td>
<td>Protein phosphatase</td>
</tr>
<tr>
<td>Z34524</td>
<td>Prckm</td>
<td>Protein kinase C, mu</td>
<td>-2.5</td>
<td>1.5</td>
<td>2.5</td>
<td>Cell growth and differentiation</td>
<td>Protein phosphatase</td>
</tr>
<tr>
<td>Y18276</td>
<td>Nbea</td>
<td>Neurobeachin</td>
<td>-3.5</td>
<td>1.8</td>
<td>2.9</td>
<td>Protein targeting</td>
<td>Protein binding</td>
</tr>
<tr>
<td>X97817</td>
<td>Sema5a</td>
<td>Sema domain, seven thrombospondin repeats</td>
<td>-3.3</td>
<td>1.1</td>
<td>3.0</td>
<td>Receptor activity</td>
<td>Transmembrane signaling</td>
</tr>
<tr>
<td>AF033655</td>
<td>Pptf1</td>
<td>PPTFAIRE protein kinase 1</td>
<td>-2.8</td>
<td>1.2</td>
<td>2.1</td>
<td>Protein phosphorylation</td>
<td>Protein kinase</td>
</tr>
<tr>
<td>AF086066</td>
<td>Gcugp2</td>
<td>CUG triplet repeat RNA binding protein 2</td>
<td>-2.8</td>
<td>1.2</td>
<td>2.1</td>
<td>Splice site selection</td>
<td>Protein phosphorylation</td>
</tr>
<tr>
<td>D38417</td>
<td>Ahr</td>
<td>Aryl-hydrocarbon receptor</td>
<td>-2.9</td>
<td>1.1</td>
<td>3.1</td>
<td>Cytoskeleton organization</td>
<td>Transcription factor</td>
</tr>
<tr>
<td>NM_011160</td>
<td>Pkg1</td>
<td>Protein kinase, cGMP-dependent, type I</td>
<td>-2.8</td>
<td>1.1</td>
<td>2.6</td>
<td>Protein phosphorylation</td>
<td>cAMP-dependent signaling</td>
</tr>
<tr>
<td>X57413</td>
<td>Tgft1</td>
<td>Transforming growth factor beta-2</td>
<td>-2.1</td>
<td>1.2</td>
<td>2.1</td>
<td>Cell differentiation</td>
<td>Growth factor</td>
</tr>
<tr>
<td>X96572</td>
<td>Figf</td>
<td>Fetal-derived PDGF family member</td>
<td>-2.1</td>
<td>1.2</td>
<td>2.0</td>
<td>Cytoskeleton organization</td>
<td>Protein binding</td>
</tr>
<tr>
<td>Z29532</td>
<td>Fst</td>
<td>Follistatin</td>
<td>-1.2</td>
<td>1.2</td>
<td>2.0</td>
<td>Differentiation</td>
<td>BMP/TGFb inhibitor</td>
</tr>
<tr>
<td>X69619</td>
<td>Inhiba</td>
<td>Inhibin-alpha</td>
<td>-1.2</td>
<td>1.2</td>
<td>2.0</td>
<td>Cell growth and differentiation</td>
<td>Growth factor activity</td>
</tr>
<tr>
<td>X62934</td>
<td>Tach1</td>
<td>Tachykinin receptor 1</td>
<td>-1.2</td>
<td>1.2</td>
<td>2.0</td>
<td>G-protein signaling pathway</td>
<td>G-protein coupled receptor activity</td>
</tr>
<tr>
<td>ABO24565</td>
<td>Hs6s2</td>
<td>Heparan sulfate 6-O-sulfotransferase 2</td>
<td>-1.3</td>
<td>1.5</td>
<td>2.0</td>
<td>Protein sulfation</td>
<td>Transferrase</td>
</tr>
<tr>
<td>X66976</td>
<td>Colla1</td>
<td>Collagen, type VIII, alpha 1</td>
<td>-1.8</td>
<td>1.3</td>
<td>2.0</td>
<td>Cell adhesion</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>U31758</td>
<td>Hdc1</td>
<td>Histone deacetylase 1</td>
<td>-1.2</td>
<td>1.1</td>
<td>2.0</td>
<td>Chromatin remodeling</td>
<td>Histone deacetylase</td>
</tr>
<tr>
<td>X61455</td>
<td>Nabl</td>
<td>N-ethylmaleimide sensitive attachment protein</td>
<td>-1.0</td>
<td>1.2</td>
<td>2.1</td>
<td>Growth factor</td>
<td>Transport</td>
</tr>
<tr>
<td>U89505</td>
<td>Snai2</td>
<td>Snail homolog</td>
<td>-1.4</td>
<td>1.1</td>
<td>2.1</td>
<td>Development</td>
<td>DNA binding</td>
</tr>
<tr>
<td>AF054623</td>
<td>Fzd1</td>
<td>Frizzled 1</td>
<td>-1.3</td>
<td>1.2</td>
<td>2.2</td>
<td>Receptor signaling</td>
<td>G-protein coupled receptor activity</td>
</tr>
<tr>
<td>U89024</td>
<td>Ppp3r1c3</td>
<td>Protein phosphatase 1 inhibitor subunit</td>
<td>-1.3</td>
<td>1.2</td>
<td>2.2</td>
<td>Protein phosphorylation</td>
<td>Protein phosphatase</td>
</tr>
<tr>
<td>AF117097</td>
<td>Sfrp4</td>
<td>Secreted frizzled-related protein 4</td>
<td>-1.3</td>
<td>1.2</td>
<td>2.5</td>
<td>Protein phosphorylation</td>
<td>G-protein coupled receptor activity</td>
</tr>
<tr>
<td>AF038507</td>
<td>Cip7</td>
<td>RIKEN cDNA 2010204K13 gene</td>
<td>-1.3</td>
<td>1.2</td>
<td>2.5</td>
<td>Protein phosphorylation</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Table 1. Genes deregulated by arsenite, BaP or both. Positive values indicate fold-increases and negative values, fold-decreases.
Fig. 1

Control

3 µM NaAsO₉

6 µM NaAsO₉

12 µM NaAsO₉

25 µM NaAsO₉

50 µM NaAsO₉

5 nM TCDD
Fig. 2

This article has not been copyedited and formatted. The final version may differ from this version.
Fig. 3
**Fig. 4**

A) Control and treated cells with different concentrations of NaAsO₂ and TCDD.

B) Western blot analysis showing protein expression levels in untreated and treated conditions.

<table>
<thead>
<tr>
<th></th>
<th>Untreated</th>
<th>1 μM 3M4NF</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td>C</td>
<td>A6</td>
</tr>
<tr>
<td>A12</td>
<td>A25</td>
<td>T</td>
</tr>
<tr>
<td>C</td>
<td>A6</td>
<td>A12</td>
</tr>
<tr>
<td>A25</td>
<td></td>
<td>A25</td>
</tr>
</tbody>
</table>
Fig. 5

**A**

![Graph A](image)

**B**

![Graph B](image)

This article has not been copyedited and formatted. The final version may differ from this version.
Fig. 6

Relative amount of mRNA

Cyp1a1

Nqo1

DMSO Control
2 µM NaAsO₂
5 µM B(a)P
2 µM NaAsO₂ + 5 µM B(a)P
25 µM tBHQ
2 µM NaAsO₂ + 25 µM tBHQ

*
Fig. 7

A. Nqo1

B. Cyp1b1

Relative amount of mRNA

0   1   2   5  1   5  1   5   5   1  5  0   1   2   5

µM NaAsO2

µM B[a]P

µM NaAsO2

µM B[a]P

Add

Syn

1   2   5

1   5   5   1   5

0   1   2   5

µM NaAsO2

25 µM tBHQ
Fig. 8

This article has not been copyedited and formatted. The final version may differ from this version.